Molecular Vision (MVL) is a CLIA-certified medical diagnostic laboratory that provides state-of-the-art genetic testing for clients worldwide. Our roots stem from the Casey Eye Institute, at the Oregon Health and Science University (OHSU), where our Director and team of lab technicians and bioinformatics scientists developed the most comprehensive test panel for inherited retinal dystrophies.
We are proud to announce that MVL is now majority owned and supported by Centrillion Biosciences, a biotechnology company based in Palo Alto, California. Our close relationship with Centrillion’s team of highly experienced genomics technology developers will allow us to bring the best and most affordable tests to our clients.
MVL Vision Panel, formerly known as the Inherited Retinal Dystrophy (IRD) Panel
A comprehensive test of vision-related, inherited conditions covering retinal dystrophy, developmental eye diseases, and pigmentation conditions, including newly identified genes such as CLUAP1 (a new LCA gene) and REEP6 (a new RP gene). Our MVL Vision Panel (v2) consists of 581 genes with an average coverage of ~700 reads and at least 30X coverage in >96% of the panel. Targeted regions cover all exons, exon-intron boundaries, and relevant, deep-intronic regions.
This new test is a capture-based panel with baits designed and manufactured by our parent company, Centrillion Technologies. Sequencing is done using the Illumina HiSeq platform with specific optimizations to maximize coverage. Variant calling and interpretation done using a combination of domain knowledge, historical data from over 2700 cases previously tested by our Retinal Dystrophy Panels, and publicly available data. Furthermore, for each order of the MVL Vision panel, we run two additional tests targeting specific hard to sequence regions using (1) gel analysis of CACNA2D4 AJ deletion, CLN3 1 kb deletion, MAK Alu insertion, and TRPM1 AJ deletion (see Chiang et al., 2017); (2) RPGR ORF15 NGS (see Chiang et al., 2018). Array CGH analysis and mitochondria genome sequencing (MVL MitoSeq Panel) can be ordered separately.
While the MVL Vision Panel helps reduce the selection bias associated with ordering smaller, targeted tests, we recognize the added complexity of a broader panel and the potential for identification of mutations not directly related to the patient’s current clinical presentation. To accommodate the varying needs of our clients, we encourage the inclusion of information related to clinical phenotype and specification of the scope of desired results with your order so that the final report can be tailored to your specific request.
In cases where no mutations or a single mutation is identified, Array CGH analysis or MVL MitoSeq Panel may be considered.
Biochemistry & Molecular Biology Services
Clinical Molecular Diagnostics Services
Molecular Vision Lab has not received any reviews.
Molecular Vision Lab has not received any endorsements.